# The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer

Source: https://onco.cc/trials/nct05550415/  
OnCo record `nct05550415` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in triple-negative breast cancer, run by Universitas Indonesia, now recruiting.

## Summary

The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer is a phase 2, randomised interventional study registered as NCT05550415 by Universitas Indonesia, with a registry enrolment figure of 26 participants, started 2022-08-19 and due to reach its primary completion in 2026-11. Interventions recorded: Simvastatin 40mg; Placebo. Conditions listed: Triple Negative Breast Cancer; Chemotherapy Effect; Simvastatin Adverse Reaction. Triple-negative eligibility wording from the registry: "Female patients with advanced breast cancer (locally advanced and distantly advanced) with triple-negative molecular type confirmed by biopsy and immunohistochemical examination". Sites: Indonesia. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT05550415
- Phase: 2
- Setting: Vimentin Expression-based Therapeutic Response in Triple Negative Breast Cancer Receiving Combination of Simvastatin and NAC: A Randomized, Double-Blind, Placebo-Controlled Trial
- Sponsor: Universitas Indonesia
- Enrolled: 26

## Sources

- ClinicalTrials.gov NCT05550415: https://clinicaltrials.gov/study/NCT05550415

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05550415.json